Tetra Discovery

Tetra Discovery Partners, founded in Grand Rapids, Michigan, is dedicated to pioneering innovative treatments for central nervous system disorders, particularly depression and schizophrenia. The company collaborates with universities to commercialize intellectual property and conducts proprietary research aimed at addressing severe forms of depression, which affect 2-5% of the U.S. population, and mood disorders, impacting 7% of the global population. Their core mission is to develop effective therapies that improve mental health and reduce disability caused by these conditions.

Notable figures associated with Tetra Discovery include leading scientists and researchers in the field of neuropsychiatry. The company has garnered attention for its promising drug candidate, BPN14770, which is currently undergoing multiple clinical trials. Tetra Discovery's achievements in advancing treatments for Fragile X syndrome and other cognitive disorders have positioned it as a significant player in medical research. Their work has the potential to make a substantial impact on the lives of millions affected by mental health conditions worldwide.